Share

EORTC abstracts selected at ESMO 2019

In total, EORTC will be presenting 3 abstracts (2 oral presentations and 1 poster) at the ESMO Congress 2019 from 27 September until 1 October in Barcelona, Spain.

Andrew Bottomley, Head of the Quality of Life at EORTC, will chair a session about “Surviving a cancer diagnosis with a good QoL” on 30 September from 8:30 to 10:00 and give a lecture on “Can value frameworks (such as ESMO-MCBS) contribute to a higher QoL?”

During the same session, Madeline Pe, EORTC Specialist in QoL, will talk about EORTC’s work on survivorship.

Meet us at our booth located in the society village n°20.

 

Oral presentations

A phase II study of Monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

R Galot, C Le Tourneau, E Saada-Bouzid, A Daste, C Even, P Debruyne, S Henry, S Zanetta, A Rutten, L Licitra, JL Canon, MC Kaminsky, P Specenier, S Rottey, L Dirix, T Raveloarivahy, C Fortpied, M Vanlancker, A Govaerts, JP Machiels  

Presentation number: 1109O

Speaker: Rachel Galot

Date: 30.09.2019 – Lecture time: 10:15 – 11:45 – Location: Cordoba Auditorium (Hall 7)

Redefining the IGCCCG Classification in advanced Non-Seminoma

Gillessen S, Collette L, Daugaard G, De Wit R, Tryakin A, Albany C, Stahl O, Fizazi K, Gietema J, De Giorgi U, Hansen AR,  Feldman D, Cafferty FH, Tandstad T, Garcia del Muro X, Huddart R, Sweeney C, Heng DY, Sauvé N and Beyer J for the IGCCCG Update Consortium

Presentation number: 903O

Speaker: Silke Gillessen

Date: 28.09.2019 – Lecture time: 15:30 – 15:45 – Location: Sevilla Auditorium (Hall 2)

 

Poster

There is a lack of clinical research for patients with cancer in palliative care

M. Vinches, A. Neven, L. Fenwarth, M. Terada, G. Rossi, S. Kelly, J. Peron, M. Thomaso, M. Groenvold, T. De Rojas

Poster number: 1610P

Poster presenter: Marie Vinches

Date: 28.09.2019 – Lecture time: 12:20 – Location: Poster Area (Hall 4)

Back to news list

Related News

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Independent, academic cancer trials are vital to improve patient outcomes worldwide

  • EORTC Imaging Group Becomes the Diagnostic and Therapeutic Imaging Group

  • Investing in the future of cancer research; EORTC’s Young and Early Career investigator Network shows its value

  • In Memoriam of Martine Van Glabbeke (1951-2026)

  • PEACE-3 trial demonstrates significant overall survival benefit in patients with metastatic castration-resistant prostate cancer with bone metastases

  • EORTC celebrates Rare Disease Day: Addressing unmet needs in rare cancers

  • First Site Activated in EORTC RENALUT Clinical Trial on Metastatic Clear Cell Renal Cell Carcinoma

  • World Cancer Day: How clinical cancer research changes lives